Ageing and Parkinson's Disease: Why is Advancing Age the Biggest Risk Factor?

Overview

Journal Ageing Res Rev

Specialty Geriatrics

Date 2014 Feb 8

PMID 24503004

Citations 373

Authors

Amy Reeve

Eve Simcox

Doug Turnbull

Affiliations

Soon will be listed here.

Abstract

As the second most common age related neurodegenerative disease after Alzheimer's disease, the health, social and economic impact resulting from Parkinson's disease will continue to increase alongside the longevity of the population. Ageing remains the biggest risk factor for developing idiopathic Parkinson's disease. Although research into the mechanisms leading to cell death in Parkinson's disease has shed light on many aspects of the pathogenesis of this disorder, we still cannot answer the fundamental question, what specific age related factors predispose some individuals to develop this common neurodegenerative disease. In this review we focus specifically on the neuronal population associated with the motor symptoms of Parkinson's disease, the dopaminergic neurons of the substantia nigra, and try to understand how ageing puts these neurons at risk to the extent that a slight change in protein metabolism or mitochondrial function can push the cells over the edge leading to catastrophic cell death and many of the symptoms seen in Parkinson's disease. We review the evidence that ageing is important for the development of Parkinson's disease and how age related decline leads to the loss of neurons within this disease, before describing exactly how advancing age may lead to substantia nigra neuronal loss and Parkinson's disease in some individuals.

Citing Articles

Proteomic and phosphoproteomic signatures of aging mouse liver.

Mohallem R, Schaser A, Aryal U Geroscience. 2025; .

PMID: 40087212 DOI: 10.1007/s11357-025-01601-0.

Longitudinal multi-omics in alpha-synuclein Drosophila model discriminates disease- from age-associated pathologies in Parkinson's disease.

Moore J, Wu T, Dhindsa J, El Fadel O, Le A, Perez A NPJ Parkinsons Dis. 2025; 11(1):46.

PMID: 40069190 PMC: 11897226. DOI: 10.1038/s41531-025-00899-z.

Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications.

Dash U, Bhol N, Swain S, Samal R, Nayak P, Raina V Acta Pharm Sin B. 2025; 15(1):15-34.

PMID: 40041912 PMC: 11873663. DOI: 10.1016/j.apsb.2024.10.004.

Progress and prospects of Parkinson's disease with depression research: A global bibliometric analysis based on CiteSpace.

Li J, You J, Li Z, Zang J, Wu L, Zhao T Medicine (Baltimore). 2025; 104(7):e41537.

PMID: 39960944 PMC: 11835133. DOI: 10.1097/MD.0000000000041537.

Nanotechnology in Parkinson's Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes.

Ali I, Adil M, Imran M, Qureshi S, Qureshi S, Hasan N Drug Deliv Transl Res. 2025; .

PMID: 39878857 DOI: 10.1007/s13346-025-01799-8.

References

Thomas K, McCoy M, Blackinton J, Beilina A, van der Brug M, Sandebring A . DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet. 2010; 20(1):40-50. PMC: 3000675. DOI: 10.1093/hmg/ddq430. View

Song L, Shan Y, Lloyd K, Cortopassi G . Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression. Hum Mol Genet. 2012; 21(23):5147-58. PMC: 3607469. DOI: 10.1093/hmg/dds365. View

Devi L, Raghavendran V, Prabhu B, Avadhani N, Anandatheerthavarada H . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283(14):9089-100. PMC: 2431021. DOI: 10.1074/jbc.M710012200. View

Martins de Brito O, Scorrano L . Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008; 456(7222):605-10. DOI: 10.1038/nature07534. View

Ma X, Liu H, Foyil S, Godar R, Weinheimer C, Hill J . Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation. 2012; 125(25):3170-81. PMC: 3397471. DOI: 10.1161/CIRCULATIONAHA.111.041814. View

Khaliq Z, Bean B . Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci. 2010; 30(21):7401-13. PMC: 2892804. DOI: 10.1523/JNEUROSCI.0143-10.2010. View

Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan E, Adalsteinsson E . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage. 2011; 59(3):2625-35. PMC: 3254708. DOI: 10.1016/j.neuroimage.2011.08.077. View

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

Arnold B, Cassady S, VanLaar V, Berman S . Integrating multiple aspects of mitochondrial dynamics in neurons: age-related differences and dynamic changes in a chronic rotenone model. Neurobiol Dis. 2010; 41(1):189-200. PMC: 3021420. DOI: 10.1016/j.nbd.2010.09.006. View

10.

van der Walt J, Nicodemus K, Martin E, Scott W, Nance M, Watts R . Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003; 72(4):804-11. PMC: 1180345. DOI: 10.1086/373937. View

11.

Bender A, Krishnan K, Morris C, Taylor G, Reeve A, Perry R . High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006; 38(5):515-7. DOI: 10.1038/ng1769. View

12.

Kastner A, Hirsch E, Lejeune O, Rascol O, Agid Y . Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J Neurochem. 1992; 59(3):1080-9. DOI: 10.1111/j.1471-4159.1992.tb08350.x. View

13.

Alemi M, Prigione A, Wong A, Schoenfeld R, DiMauro S, Hirano M . Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript. Free Radic Biol Med. 2006; 42(1):32-43. PMC: 1927835. DOI: 10.1016/j.freeradbiomed.2006.09.014. View

14.

Bendor J, Logan T, Edwards R . The function of α-synuclein. Neuron. 2013; 79(6):1044-66. PMC: 3866954. DOI: 10.1016/j.neuron.2013.09.004. View

15.

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

16.

Ottolini D, Cali T, Negro A, Brini M . The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum Mol Genet. 2013; 22(11):2152-68. DOI: 10.1093/hmg/ddt068. View

17.

Davidzon G, Greene P, Mancuso M, Klos K, Ahlskog J, Hirano M . Early-onset familial parkinsonism due to POLG mutations. Ann Neurol. 2006; 59(5):859-62. DOI: 10.1002/ana.20831. View

18.

Reddy P, Tripathi R, Troung Q, Tirumala K, Reddy T, Anekonda V . Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2011; 1822(5):639-49. PMC: 3272314. DOI: 10.1016/j.bbadis.2011.10.011. View

19.

Huerta C, Castro M, Coto E, Blazquez M, Ribacoba R, Guisasola L . Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J Neurol Sci. 2005; 236(1-2):49-54. DOI: 10.1016/j.jns.2005.04.016. View

20.

Martin L, Pan Y, Price A, Sterling W, Copeland N, Jenkins N . Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006; 26(1):41-50. PMC: 6381830. DOI: 10.1523/JNEUROSCI.4308-05.2006. View